TrialCompass TCL
Back to results
Phase 2RecruitingPriority 3 · Moderate priorityNCT06583083

Sintilimab With P-GEMOX Versus the P-GEMOX in the Teatment of Advanced-stage Extranodal Natural Killer/T Cell Lymphoma

ClinicalTrials.gov

Plain-language summary

This Phase 2 trial is comparing different first-line treatment approaches for people newly diagnosed with NK/T-cell lymphoma. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

Who can join (key eligibility)

  • Age 18 Years or older
  • Newly diagnosed, not yet treated

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Sintilimab with P-GEMOX Regimen (DRUG): Sintilimab intravenous drip, Pegaspargase intramuscular injection, gemcitabine intravenous drip, oxaliplatin intravenous drip | P-GEMOX Regimen (DRUG): Pegaspargase intramuscular injection, gemcitabine intravenous drip, oxaliplatin intravenous drip

Drugs / treatments
Sintilimab with P-GEMOX Regimen, P-GEMOX Regimen
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

Sintilimab With P-GEMOX Versus the P-GEMOX in the Teatment of Advanced-stage Extranodal Natural Killer/T Cell Lymphoma

NCT06583083

Phase: Phase 2 | Status: Recruiting | Priority: Medium

Plain-language summary

This Phase 2 trial is comparing different first-line treatment approaches for people newly diagnosed with NK/T-cell lymphoma. Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

Who can join

  • Age 18 Years or older
  • Newly diagnosed, not yet treated

What's being tested

Sintilimab with P-GEMOX Regimen (DRUG): Sintilimab intravenous drip, Pegaspargase intramuscular injection, gemcitabine intravenous drip, oxaliplatin intravenous drip | P-GEMOX Regimen (DRUG): Pegaspargase intramuscular injection, gemcitabine intravenous drip, oxaliplatin intravenous drip

Drugs / treatments: Sintilimab with P-GEMOX Regimen, P-GEMOX Regimen

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Randomized, open-label

Enrollment target: 84 patients

Primary endpoint: PFS

Ages: 18 Years to —

Start date: 2024-10-22 | Est. completion: 2026-08-28

Locations

0 US sites · 1 total

Contact

Cai Qingqing, MD.PhD | caiqq@sysucc.org.cn | (020)87342823

Sponsor: Sun Yat-sen University (OTHER)

Tags

ENKTL · Newly diagnosed · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT06583083

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.